LENZ insider Form 4 shows option exercise and planned share sales

Q: What insider transaction did LENZ Therapeutics (LENZ) report on this Form 4?

The Chief Commercial Officer exercised an option to buy 10,000 shares of LENZ common stock at $2.08 per share and then sold those 10,000 shares in two trades on 11/17/2025 .

Q: At what prices were LENZ Therapeutics (LENZ) shares sold by the officer?

The officer sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669 , with individual sale prices ranging from $25.12 to $26.81 .

Q: How many LENZ Therapeutics (LENZ) shares and options does the officer hold after the transactions?

Following the reported trades, the officer directly owned 4,733 shares of common stock and held 53,241 stock options .

Q: Were the LENZ Therapeutics (LENZ) insider sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan that the reporting person entered into on August 12, 2025 .

Q: What is the source of the exercised LENZ Therapeutics (LENZ) stock option?

The option was granted under the LENZ Therapeutics Operations, Inc. 2020 Equity Incentive Plan , with vesting that began on April 26, 2021 .

Q: What is the role of the reporting person at LENZ Therapeutics (LENZ)?

The reporting person is an officer of LENZ Therapeutics, serving as its Chief Commercial Officer , and filed the Form 4 as a single reporting person.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. (LENZ) reported a Form 4 for its Chief Commercial Officer, who executed an option exercise and related stock sales on 11/17/2025. The officer exercised a stock option to acquire 10,000 shares of common stock at $2.08 per share, then sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669. After these transactions, the officer directly held 4,733 shares of common stock and 53,241 stock options. The sales were made under a Rule 10b5-1 trading plan entered into on August 12, 2025, which is a pre-arranged plan intended to structure trading in advance.

Insider Trade Summary

Net Seller: 10,000 shares ($261,022)

Net Sell 4 txns

Insider Olsson Shawn

Role Chief Commercial Officer

Sold 10,000 shs ($261K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$2.08	$21K
Sale	Common Stock	4,212	$25.7385	$108K
Sale	Common Stock	5,788	$26.3669	$153K

Holdings After Transaction: Stock Option (right to buy) — 53,241 shares (Direct); Common Stock — 14,733 shares (Direct)

Footnotes (1)

The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025. Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.

Form 4 Insider Transactions: What Each Field Means →

11/19/2025 - 07:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olsson Shawn

(Last)

(First)

(Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE, SUITE 300

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		M		10,000	A	$2.08	14,733	D
Common Stock	11/17/2025		S⁽¹⁾		4,212	D	$25.7385⁽²⁾	10,521	D
Common Stock	11/17/2025		S⁽¹⁾		5,788	D	$26.3669⁽³⁾	4,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.08	11/17/2025		M			10,000	⁽⁴⁾	08/18/2031	Common Stock	10,000	$0	53,241	D

Explanation of Responses:

1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025.

2. Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LENZ Therapeutics (LENZ) report on this Form 4?

The Chief Commercial Officer exercised an option to buy 10,000 shares of LENZ common stock at $2.08 per share and then sold those 10,000 shares in two trades on 11/17/2025.

At what prices were LENZ Therapeutics (LENZ) shares sold by the officer?

The officer sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669, with individual sale prices ranging from $25.12 to $26.81.

How many LENZ Therapeutics (LENZ) shares and options does the officer hold after the transactions?

Following the reported trades, the officer directly owned 4,733 shares of common stock and held 53,241 stock options.

Were the LENZ Therapeutics (LENZ) insider sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan that the reporting person entered into on August 12, 2025.

What is the source of the exercised LENZ Therapeutics (LENZ) stock option?

The option was granted under the LENZ Therapeutics Operations, Inc. 2020 Equity Incentive Plan, with vesting that began on April 26, 2021.

What is the role of the reporting person at LENZ Therapeutics (LENZ)?

The reporting person is an officer of LENZ Therapeutics, serving as its Chief Commercial Officer, and filed the Form 4 as a single reporting person.